CureVac COVID-19 vaccine
The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate created by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[1]
The vaccine showed bad results in its Phase III trials with only 47% effective.[2] The vaccine was never sold.[3]
References
- ↑ "CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". Press release. 15 March 2020. Archived from the original on 8 March 2021. https://web.archive.org/web/20210308065100/https://www.curevac.com/en/2020/03/15/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide/. Retrieved 17 February 2021.
- ↑ Burger, Ludwig (2021-06-16). "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy" (in en). Reuters. https://www.reuters.com/article/us-health-coronavirus-curevac-trial-idUSKCN2DS2EU. Retrieved 2021-06-17.
- ↑ CureVac drops COVID-19 vaccine, pins hope on next-generation shots. Reuters. 2021-10-12. https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-withdraw-first-generation-covid-19-vaccine-candidate-2021-10-12/. Retrieved 2021-12-30.
